About US
Contact us
-
Bristol-Myers, Roche will top burgeoning I-O market worth $29B: analystBristol-Myers Squibb may be falling behind in the metastatic cancer race, and Roche is dealing with biosimilarattacks on its top-selling drugs. But the two companies are the front-runners in the argua2019/1/25
-
Washington takes 'Netflix' hep C drug pricing further with winner-take-all biddingIt’s not just Louisianaworking to tackle hepatitis C by purchasing drugs in a novel way.Officials in Washington are taking that state's Netflix-style subscription model and upping the ante with a winn2019/1/24
-
Johnson & Johnson, AbbVie shore up Imbruvica's CLL lead with Gazyva combo winAdd another indication for Imbruvica in chronic lymphocytic leukemia to the list. On Monday, partners AbbVie and Johnson & Johnsonsaidthe standout drug had picked up another FDA approval in the d2019/1/24
-
CVS puts Amgen's Aimovig in back seat behind Teva, Lilly migraine drugsAmgen may have the first-mover advantage in the new class of CGRP migraine prevention drugs, but the company didn't get top billing with one major pharmacy benefits manager. CVS gave that to Teva and2019/1/23
-
AstraZeneca's latest value-based pact serves up Brilinta at generic-level copaysAstraZeneca is no stranger to value-based pricing agreements, even for heart drug Brilinta,but its latest is different. The company has struck a deal with UPMC Health Plan that links reimbursement fo2019/1/23
-
FDA panel split on Sanofi's Type 1 diabetes hopeful ZynquistaShould the FDA approve Sanofi’s SGLT1/2 candidate for patients with Type 1 diabetes? Turns out, the experts can’t agree. On Thursday, an advisory panel was split—voting 8-8—on whether the overall ben2019/1/22
-
On heels of Loxo buy, Lartruvo setback deals a blow to Lilly's oncology hopesAfter patent expirations and other woes,Eli Lilly has been leaning on a stable of new drugs for growth. But aftera trial failure for soft tissue sarcoma launch Lartruvo, the drugmaker is stopping prom2019/1/22
-
Sun Pharma drops to 6-year low on report of another whistleblower complaintJust weeks after Sun Pharma’s stock was hit by whistleblower allegations of insider trading, a second complaint reportedly filed to Indian regulators sent the drugmaker’s shares tumbling to a new six-2019/1/21
-
Lilly price break reverses NICE’s 'No' ruling on breast cancer drug VerzenioLast October, England’s drug-cost watchdogs dealt Eli Lilly a blow when they decreedthat the company’s CDK 4/6 inhibitor to treat breast cancer, Verzenio, wasn'tcost-effective. So Lilly dished up a ne2019/1/21
-
AstraZeneca licences Luye Pharma cholesterol drug in ChinaLuye Pharma has granted AstraZeneca’s Chinese division exclusive rights to promote its cholesterol medicine Xuezhikang Capsules in mainland China. The drug, made by fermenting red yeast rice, is indi2019/1/18